



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>A61K 38/00, A61K 38/24, A61K 38/27</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/43029</b> (43) International Publication Date: 27 July 2000 (27.07.2000)
(21) International Application Number: <b>PCT/US00/01535</b> (22) International Filing Date: <b>21 January 2000 (21.01.2000)</b> (30) Priority Data: <b>09/234,591 21 January 1999 (21.01.1999) US</b> (60) Parent Application or Grant <b>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [/]; O. SHABSIGH, Ridwan [/]; O. WHITE, John, P. ; O.</b>	<b>Published</b>	
(54) Title: <b>USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE TREATMENT OF ERECTILE DYSFUNCTION</b> (54) Titre: <b>UTILISATIONS DU FACTEUR DE CROISSANCE VASCULAIRE ENDOTHELIALE POUR LE TRAITEMENT DE LA DYSERECTION</b>		
(57) Abstract <p>This invention provides a method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis. This invention provides a method of treating erectile dysfunction in a subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction. This invention provides a method of increasing or maintaining the blood supply in the penis of a subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis. This invention provides a method of increasing or maintaining the blood supply in the genital area of a female subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's genital area.</p> <p>(57) Abrégé <p>L'invention concerne un procédé permettant d'augmenter ou d'entretenir l'irrigation sanguine du pénis chez un sujet mâle et consistant en l'administration à ce sujet d'une quantité suffisante de VEGF (Vascular Endothelial Growth Factor) ou "facteur de croissance vasculaire endothéliale" pour augmenter ou entretenir l'irrigation sanguine du peins du sujet. L'invention concerne un procédé permettant de traiter la dysérection chez un sujet, et consistant en l'administration au sujet d'une quantité de VEGF suffisante pour augmenter l'irrigation sanguine du pénis du sujet et ainsi de traiter la dysérection du sujet. L'invention concerne un procédé permettant d'augmenter ou d'entretenir l'irrigation sanguine du pénis chez un sujet mâle et consistant en l'introduction d'un acide nucléique comprenant un gène codant pour un VEGF introduit dans une cellule appropriée dans des conditions telles que l'acide nucléique vienne exprimer le VEGF de façon à augmenter ou entretenir l'irrigation sanguine du pénis du sujet. L'invention concerne un procédé permettant d'augmenter ou d'entretenir l'irrigation sanguine de la sphère génitale d'un sujet femelle et consistant en l'administration à ce sujet d'une quantité de VEGF suffisante pour augmenter l'irrigation sanguine de la sphère génitale du sujet.</p></p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Description

5

10

15

20

25

30

35

40

45

50

55

5

USES OF VASCULAR ENDOTHELIAL GROWTH  
FACTOR IN THE TREATMENT OF ERECTILE DYSFUNCTION

10

5 This application claims priority of U.S. Serial No. 09/234,591, filed January 21, 1999, the contents of which is hereby incorporated by reference.

15

20

Throughout this application, various publications are referenced by Arabic numerals. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.

15

Background of the Invention

25

30

35

Mammalian reproduction requires a physiological stimulation of male erectile tissues in the penis to mechanistically support the transfer of sperm from the male to the female. Obviously then, defects that prevent an appropriate erectile tissue response can drastically interfere with reproductive capability. In humans, erectile dysfunction is considered to be a disease state and is referred to as the condition of "impotence". This condition impacts on the quality of life both of the male patients, as well as their wives/partners (1).

40

45

50

Erection is a hemodynamic phenomenon involving the tissue of the corpora cavernosa as well as the corpus spongiosum in the penis. This tissue is a complex admixture of smooth muscle, endothelial cells, fibroblasts and nerves interacting under stimulatory conditions to drastically enhance and maintain an accessory blood supply that imparts rigidity to the penis. Given the need for stringent control of blood flow during this response, it is no surprise that vascular insufficiency has the ability to drastically suppress erectile capability. In fact, penile vascular insufficiency is believed to be a very common pathomechanism of erectile dysfunction (2). This

55

5 is associated with substantial pathologic changes in the  
erectile tissue leading to reduction in vascular smooth  
muscle cells and increases in collagen and fibrosis (3-6).

10 5 The currently available treatments of erectile dysfunction  
induce temporary erections at the same time of administration  
of such treatments. However, these treatments do not address  
15 or cure the basic vascular/cavernosal pathology causing  
erectile dysfunction. The rationale for a curative treatment  
10 that improves or repairs the vascular structure and function  
of the erectile tissue is based upon the understanding of  
erectile physiology and the pathophysiology of vascular  
20 erectile dysfunction. Consequently, it is prudent to pursue  
investigation of factors that induce new vascular structure  
15 formation or vasculogenesis. Several naturally occurring  
growth factors have been found to induce vasculogenesis  
25 (7-10). Such growth factors include the vascular endothelial  
growth factor (VEGF) family (11), the fibroblast growth  
factor (FGF) family (12,13), transforming growth factor  
20 -alpha and -beta (TGF) (14), and platelet derived growth  
factor (PDGF) (15-17). Vascular endothelial growth factor  
30 (VEGF) may well be one of the most potent and interesting of  
these vascular growth factors. It is thought to play a role  
in embryonic vasculogenesis (18), maintenance of vascular  
35 structures in the adult and formation of new blood vessels  
in the adult in responses to ischemia and other pathologic  
states. Therapies that increase tissue levels of VEGF in  
laboratory animals or humans with peripheral vascular disease  
40 have resulted in a measurable increase in tissue vascularity  
30 (19-24).

45 In order to contemplate the potential of VEGF therapy for  
erectile dysfunction, a characterization was wanted of the  
extent to which VEGF is expressed in the mammalian penis and  
35 in erectile tissue, as well as a determination of which of  
the known isoforms of VEGF (derived from mRNA splice site  
variation) are most abundantly present in this tissue  
50 compared to other mammalian tissues. Here a survey of VEGF

5 isoform expression (mRNA) in mature rat penis and in human  
erectile tissue is presented.

10 VEGF is a growth factor that acts preferentially on  
5 endothelial cells(18). With the current focus of biomedical  
research on angiogenesis, the biology of VEGF has been under  
intense scrutiny. In humans, there are several different  
15 genes that encode VEGF-like proteins (49,50), the most  
studied of these genes is that for VEGF-A (51,52,53). As  
10 described by several different laboratories, the VEGF-A gene  
gives rise to several different mature mRNA transcripts that  
differ in the protein products they encode (33,34). These  
20 variant transcripts arise through an alternative splicing  
mechanism (30,31,54) and the abundance of any particular  
15 VEGF-A transcript differs, depending on the tissue examined  
(28). The most predominant VEGF-A transcripts found in adult  
25 tissues encode proteins of 188/189, 164/165 and 120/121 amino  
acids (rat/human) (28,35). Other, rarer variant transcripts  
arising from VEGF-A have also been reported (encoding 205/206  
20 and 144/145 amino acid proteins), but these forms were only  
found in a few tissues, mainly fetal in origin (VEGF 205/206:  
30 human fetal liver (32), sheep (41) and human placenta (42)/  
VEGF 144/145: human uterus (39), human endometrial carcinoma  
cells (39), sheep (41) and human placenta (42),  
35 respectively). During a preliminary survey of adult penile  
tissues for the expression of VEGF-A isoforms, it was found  
that the expression of VEGF-A mRNA splice variants encoding  
the 205/206 and 144/145 forms of VEGF can be identified by  
40 standard RT-PCR techniques and confirmed by cloning and  
30 sequencing from other adult rat and human tissues and  
cultured cells. These results suggest that these rarer  
splice variants of VEGF-A might have a wider tissue  
45 distribution than originally anticipated.

50

55

5

Summary of the Invention:

10

This invention provides a method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

15

This invention provides a method of treating erectile dysfunction in a subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction.

20

25

This invention provides a method of increasing or maintaining the density of vascular structures in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

30

This invention provides the above methods, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.

35

This invention provides the above methods, wherein the vascular endothelial growth factor is administered intravenously, topically, transdermally, orally or by injection.

40

This invention provides the above methods, wherein the vascular endothelial growth factor is injected into the penis.

45

This invention provides the above methods, wherein the vascular endothelial growth factor is injected into corpora cavernosa or corpus spongiosum tissue.

50

This invention provides a method of increasing or maintaining

55

5

the blood supply in the penis of a subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses

10 5 vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis.

15

This invention provides a method of increasing or maintaining the blood supply in the genital area of a female subject

10 15 which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's genital area.

20

15

25

30

20

35

40

45

50

55



Brief Description of the Figures:

Figure 1

Diagram characterizing some major VEGF-A cDNA splice variants isoforms that were previously detected in rat tissues and were also observed in the study:

The mammalian VEGF gene is split into eight exons (represented by boxes). Alternative splicing of these exons give rise to six molecular forms previously detected in rat tissues (VEGF 205 amino acids - 120 amino acids) as well as a form (VEGF 110 amino acids) that was discovered by our screening and sequencing of VEGF cDNA clones from the rat penis. The nucleotide length of the exon boxes is described above the VEGF 205 form and below the VEGF 110 form.

Figure 2

RT-PCR characterization of VEGF-A cDNA splice variants expressed in rat and human tissues:

(A) Agarose gel profile of products resulting from RT-PCR amplification of VEGF-A mRNA splice variants present in rat tissues. Both rat lung and penis show presence of cDNA products characteristic of amplification of VEGF-A splice forms 188, 164, 144 and 120. These cDNA amplification products migrate equivalently with the characterized VEGF isoform markers present individually in the lanes on the right as marked. Whereas 188 form appears to more predominant in lung, the 164 form appears to be most abundant in penis. M.W. = lanes containing molecular weight markers.

(B) Agarose gel profile of products resulting from RT-PCR amplification of VEGF-A mRNA splice variants present in human cells and tissue. Both the LNCaP cell line RNA and human cavernosal RNA allow the amplification of 4 major splice variants of VEGF A (189, 165, 145 and 121). As with the results from amplification of rat penis RNA (4th lane), the 165 AA splice variant is more abundant in human penis than the 189 splice variant. Similarly amplified products from rat tissues (penis and lung) are compared on right

lanes. M.W. = Lane containing molecular weight marker. Molecular sizes of amplified fragments are shown on the right.

Figure 3  
RNase protection assays of RNAs extracted from rat lung or penis to measure relative abundance of VEGF-A mRNA splice variant expression:

(A) RNase protection assay using 32P-labeled large (VEGF 188) antisense riboprobe. Autoradiograph of gel containing RNase digestion products reveals the presence of a protected 564 bp fragment characterizing abundant expression of VEGF 188 splice variant only in rat lung, not in rat penis mRNA.

(B) RNase protection assay using 32P-labeled small (VEGF 164) antisense riboprobe. Autoradiograph of gel containing RNase digestion products reveals the presence of abundant 150 bp protected fragment in lung, not penis RNA, confirming abundant expression of 188 splice variant in this site. Likewise the presence of a 492 bp protected fragment in both rat lung and penis RNA characterizes expression of the VEGF 164 splice isoform in both tissues. Finally, the presence of 342 bp protected fragment in penis RNA, while potentially resulting from hybridization with the 188 or 144 splice forms, is most likely to result from the digestion of an abundant VEGF 120 splice isoform in the penis based on our inability to detect protection of the other specific fragments that would result from hybridization of the large (VEGF 188) probe with the 188 or 144 splice variants. Diagrams (at lower part of figures) identify the size of potential protected fragments that could result using the larger probe (A) or the smaller VEGF probe (B). Sizes of molecular weight markers (M.W.) are indicated to the right, sizes of specifically designated protected fragments are indicated to the left. Control lanes include yeast RNA hybridized to probe + digestion or

5

yeast RNA hybridized to probe - digestion.

Figure 4

10

RT-PCR amplification demonstrates VEGF splice isoform (144/145) expression in rat and human tissues and cells:

5

15

PCR primers within exon 1 and 8 of VEGF-A were used to amplify cDNA from rat lung and penis or from human penis or LNCaP cell lines. Agarose gel of reaction products stained with ethidium bromide. Arrows show position of bands at

20

360/363 bp (VEGF 120/121), 432/435 bp (VEGF 144/145), 492/495 bp (VEGF 164/165) and 564/567 bp (VEGF 188/189).

25

Right side of gel contains a representative ladder generated by PCR-amplification of individual clones containing the referenced VEGF cDNA fragment or a molecular weight marker (M.W.)

25

Figure 5

30

RT-PCR amplification demonstrates VEGF splice isoform (VEGF 205) expression in rat tissues:

35

20 PCR primers within exon 1 and 6B of VEGF-A were used to amplify cDNA from adult rat lung and penis. Agarose gel of reaction products stained with ethidium bromide. Arrow show position of bands at 433bp (VEGF 205). Right lanes contain RT-PCR reaction products using exon 1/8 primers on rat tissues or cloned plasmids containing defined splice variant cDNA for VEGF-A as indicated. M.W. is a molecular weight marker.

40

30

45

50

55

5

Detailed Description of the Invention

10

This invention provides a method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

15

10 As used herein, "increasing" means that the blood supply is at a level that is higher than that which would exist in a control experiment without using said method.

20

As used herein, "maintaining" means that the blood supply is kept at a level which is greater than or equal to the blood supply that exists in a control situation without using said method.

25

As used herein, "subject" includes any animal or artificially modified animal. This includes but is not limited to animals such as mice, rats, dogs, guinea pigs, ferrets, rabbits, primates, equine, bovine, avian, caprine, canine, feline. As used herein, "subject" also includes a human. In the preferred embodiment, the subject is human.

30

35

25 This invention provides a method of treating erectile dysfunction in a subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction.

40

As used herein, "treating" means either slowing, stopping or reversing erectile dysfunction. In the preferred embodiment, treating means reversing to the point of eliminating erectile dysfunction.

45

50

This invention provides a method of increasing or maintaining the density of vascular structures in the penis of a male

55

5 subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

10 5 This invention provides the above methods, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A-188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.

15 10 As used herein, "VEGF-A 205/206" refers to the VEGF-A rat 205 amino acid splice variant or VEGF-A human 206 amino acid splice variant.

20 As used herein, "VEGF-A 188/189" refers to the VEGF-A rat 188 amino acid splice variant or VEGF-A human 189 amino acid splice variant.

25 As used herein, "VEGF-A 164/165" refers to the VEGF-A rat 164 amino acid splice variant or VEGF-A human 165 amino acid splice variant.

30 As used herein, "VEGF-A 144/145" refers to the VEGF-A rat 144 amino acid splice variant or VEGF-A human 145 amino acid splice variant.

35 25 As used herein, "VEGF-A 120/121" refers to the VEGF-A rat 120 amino acid splice variant or VEGF-A human 121 amino acid splice variant.

40 30 As used herein, "VEGF-A 110" refers to the VEGF-A human 110 amino acid splice variant.

45 This invention provides the above methods, wherein the vascular endothelial growth factor is administered intravenously, topically, transdermally, orally or by injection.

50 This invention provides the above methods, wherein the

5

vascular endothelial growth factor is injected into the penis.

10

This invention provides the above methods, wherein the vascular endothelial growth factor is injected into corpora cavernosa tissue.

15

This invention provides the above methods, wherein the vascular endothelial growth factor is injected into corpus spongiosum tissue.

20

This invention provides a method of increasing or maintaining the blood supply in the penis of a subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis.

25

30

As used herein, the term "nucleic acid," refers to either DNA or RNA. "Nucleic acid sequence" or "polynucleotide sequence" refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes both self-replicating plasmids, infectious polymers of DNA or RNA and nonfunctional DNA or RNA.

35

40

As used herein, "suitable" means a cell which can express the vascular endothelial growth factor gene such that it produces vascular endothelial growth factor to thereby increase or maintain the blood supply in the subject's penis.

45

The term "vector", refers to viral expression systems, autonomous self-replicating circular DNA (plasmids), and includes both expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an "expression vector," this includes both extrachromosomal circular DNA and DNA that has been

50

55

5 incorporated into the host chromosome(s). Where a vector is  
being maintained by a host cell, the vector may either be  
10 stably replicated by the cells during mitosis as an  
autonomous structure, or is incorporated within the host's  
5 genome.

This invention provides the above method, wherein the nucleic  
15 acid comprises a vector.

10 As used herein, "vector" includes viral expression systems,  
autonomous self-replicating circular DNA plasmids and  
includes both expression and nonexpression plasmids.

20 This invention provides a method of increasing or maintaining  
the density of vascular structures in the penis of a subject  
25 which comprises introducing a nucleic acid comprising a gene  
encoding a vascular endothelial growth factor into a suitable  
cell under conditions such that the nucleic acid expresses  
vascular endothelial growth factor so as to thereby increase  
20 or maintain the blood supply in the subject's penis.

30 This invention provides a method of increasing or maintaining  
the blood supply in the genital area of a female subject  
which comprises administering to the subject an amount of  
35 25 vascular endothelial growth factor effective to increase or  
maintain the blood supply in the subject's genital area.

40 This invention provides a method of increasing or maintaining  
the density of vascular structures in the genital area of a  
30 female subject which comprises administering to the subject  
an amount of vascular endothelial growth factor effective to  
increase or maintain the blood supply in the subject's  
45 genital area.

35 This invention will be better understood from the  
Experimental Details which follow. However, one skilled in  
50 the art will readily appreciate that the specific methods and  
results discussed are merely illustrative of the invention

5

as described more fully in the claims which follow  
thereafter.

10

5

15

20

25

30

35

40

45

50

55



## Experimental Details

### A. Materials and Methods

#### 1. Human Tissues

5 Specimens of cavernosal tissue of (12) humans (ages 39 -79)  
were surgically removed from the penoscrotal junction at the  
time of penile prosthesis implantation under an IRB-approved  
15 protocol. These biopsies measured approximately 5x5x10 mm.  
The specimens were immediately frozen under liquid nitrogen  
10 and were stored at -70°C until processing.

#### 2. Laboratory Animals and Tissues

Age-matched male Sprague Dawley rats (8 weeks, Camm  
Laboratories, Camden, New Jersey), were obtained under an  
15 IACUC approved protocol and were maintained on a 12 hour  
daylight cycle with food and water available ad libitum. Rats  
25 were sacrificed by a lethal overdose of sodium pentobarbital.  
Lung and penis were harvested immediately. Penile tissue was  
obtained through a circular incision made at the corona with  
30 subsequent removal of the foreskin and the shaft skin and  
amputation of the penis. The glans, which contains a  
significant amount of skin, was also removed. Excess blood  
was removed by gently blotting the penis on sterile cotton  
gauze and the specimen was flash frozen in liquid nitrogen  
35 and stored at -70°C until use. This procedure provided  
cryopreserved, deskinning penile shafts that contained mostly  
erectile tissue.

#### 3. RNA Extraction

30 Tissue (pooled penis from 20 rats or pooled 12 human  
specimens) was first pulverized under liquid nitrogen to a  
fine powder. Total RNA was isolated from the tissue powder  
45 using an RNazol (Tel-Test, Inc., Friendswoods, Tx) extraction  
procedure following the manufacturers protocol [25,26]. RNA  
35 concentration was determined by spectrophotometry at 260 nm,  
and to ensure the RNA was not degraded, each sample was  
50 analyzed by electrophoresis on a 1% denaturing formaldehyde

5 gel. Total RNA was extracted from the prostate carcinoma cell line, LNCaP, using a modification of this procedure [27].

10 4. RT-PCR to Amplify VEGF cDNAs

5 1ug total RNA was used for first-strand cDNA synthesis. The RNA was annealed to 0.5 ug oligo(dT) primer (Gibco BRL, Grand Island, N.Y.) in a volume of 20 ul at 70 °C for 10 min. then chilled on ice quickly for 2 min.. 10 mM dNTPs , 5x 1st strand buffer, 0,1 M dithiothreitol (DTT), 10 U RNase Inhibitor (Gibco BRL), and 200 U Superscript II reverse transcriptase (Gibco BRL) in a final volume of 50 ul were added. The reaction mix was incubated by heating 37°C for 90 min, and the cDNA was stored at -20 C until used.

15 Polymerase chain reaction (PCR) techniques were then used to identify the presence of VEGF isoforms in the RNA samples. Primers used for the amplification assay were slight modifications of those published previously [28]. Because these primers initiate within the first exon and terminate 20 within the eighth exon of VEGF-A, they enable amplification of all the known VEGF splice variants.

The oligonucleotide sequences of the primers used are as follow:

25 Primer 5'  
Species human  
Location start of exon 1  
Nucleotide sequence 5' TGC ACC CAT GGC AGA AGG AGG 3'

30 Primer 3'  
Species human  
Location end of exon 8  
Nucleotide sequence 5' TCA CCG CCT CGG CTT GTC ACA 3'

35 Primer 5'  
Species rat  
Location start of exon 1  
Nucleotide sequence 5' TGC ACC CAC GAC AGA AGG GGA 3'

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Primer	3'
Species	rat
Location	end of exon 8
5 Nucleotide sequence 5' TCA CCG CCT TGG CTT GTC ACA T 3'	

The PCR reaction mix contained 10x reaction buffer (100mM Tris, 500mM KCL, 1.5 mM MgCl<sub>2</sub>, pH 8.3), d NTP Mix (10mM each dATP, dGTP, dCTP and dTTP at neutral pH), 100 pmol upstream primer (5'- human/5'- rat), 100 pmol downstream primer (3'-human/3'-rat), 2.5 U Taq DNA polymerase (Boehringer Mannheim Biochemicals, Indianapolis, IN), 10 ul cDNA, and sterile water to 50 ul. PCR was carried out using a DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT) as follows: 94°C for 7 min.; then 35 cycles of denaturation at 94°C for 1 min., annealing and extension at 72°C for 1 min. each. The PCR products (20 ul of lung-rat-/LNCaP- and 35 ul of penis-rat-/penis-human-reaction mix) were analyzed by electrophoresis on a 2 % agarose gel that was subsequently stained with ethidium bromide for visualization of DNA bands. A 100 base pair ladder DNA molecular weight marker was used (Boehringer Mannheim Biochemicals) to provide a size reference for the test reactions.

#### 5. Cloning and Sequencing of RT-PCR products

1ul of penis-rat-PCR products were ligated into the pGEM-T easy Vector DNA and were used to transform DH5- (competent cells. Transformants containing cDNA inserts were characterized for insert size by analysis of Eco RI digested minipreps. A variety of plasmid vectors containing cDNA inserts of different sizes were then sequenced from the double-stranded templates by standard dideoxynucleotide sequencing techniques. These sequences were compared to the human or rat VEGF cDNA sequences present in genbank to identify exon structure.

#### 6. RNase Protection Assay for VEGF mRNA isoforms

Two antisense RNA probes for VEGF cDNA were used. One was in vitro transcribed from an Apa I-digested vector containing the rat VEGF 164 splice isoform cDNA whereas the other was in vitro transcribed from an Apa I-digested vector containing the rat VEGF 188 splice isoform DNA using SP6- polymerase. The in vitro transcription reactions were carried out in the presence of 250 uCi [<sup>32</sup>P]-UTP (NEN Life Science Products, Boston, MA) using the reagents provided in an in vitro-transcription kit (MAXIscript, Ambion, Inc., Austin, TX) according to the manufacturer's instructions. Individual labeled antisense probes (619 bases for the VEGF 164 probe and 691 bases for the VEGF 188 probe) were purified by electrophoresis on a denaturing 5% acrylamide gel and were then eluted from the gel into elution buffer (from RPA II kit, Ambion, Inc.). These probes were used in solution hybridization procedures with 20 ug of rat lung RNA or 30 ug of penis RNA using the manufacturer's recommendations provided in the RNase assay kit (RPA II, Ambion, Inc.) overnight. Hybridized specimens were digested with a nuclease cocktail provided in the RPA II kit and the digests were subsequently analyzed by electrophoresis on 5% acrylamide sequencing gels adjacent to molecular weight marker lanes.

Some control reactions included labeled probes hybridized with yeast RNA (20ug) (with/without RNase digestion). Gels were exposed to Kodak XAR-5 film to produce an autoradiograph showing the presence of RNase-protected bands.

#### B. Results and Discussion

Erectile dysfunction is often associated with problems in vascular perfusion to the erectile components of the penis. In order to better understand the factors that control vascular formation and perfusion in the erectile tissues of the penis, we have begun to characterize the expression of vascular endothelial growth factor (VEGF) in penis tissues.

5 VEGF is one of several polypeptides that has significant  
angiogenic activity in vitro and in vivo. Extensive  
characterization of the VEGF gene and its products has shown  
10 that several different mature mRNA transcripts exist,  
5 originating from alternative splicing of the basic VEGF  
transcript. These variant transcripts can encode peptides  
with different biological activities.

15 Penile tissue was obtained from adult rats and from human  
10 patients undergoing penile prosthesis implantation. Analysis  
of the forms of VEGF transcripts was performed using a  
reverse transcriptase-polymerase chain reaction (RT-PCR)  
20 technique with primer pairs derived from the first and eight  
exon of the VEGF gene. The expression levels of the various  
15 isoforms in the rat penis were then quantified using RNase  
Protection Assays. Four previously described splice  
25 variants of VEGF mRNA (VEGF 120,144,164,188) were detected  
in rat and human penile tissues. In contrast to rat lung  
where the most abundant form of VEGF mRNA is the 188 splice  
20 isoform, VEGF 164 is the most abundant transcript detected  
30 in the penis. Finally, sequence analysis of numerous VEGF  
cDNA clones obtained from rat penis demonstrated the presence  
of a previously undescribed VEGF splice variant that could  
give rise to a protein of 110 amino acid residues (VEGF 110,  
35 25 GenBank accession number AF080594<sup>3</sup>). In summary, a number of  
VEGF mRNA isoforms are expressed in the rat and human penis  
with the splice variant encoding a 164 amino acid protein  
present in greatest abundance. This study is a prelude for  
40 attempts to genetically manipulate VEGF expression in the  
30 penis as a therapy for erectile dysfunction.

45 1. RT-PCR Analysis of VEGF mRNA Splice Variant Expression  
in Rat and Human Penis

35 The mammalian VEGF gene [29] is known to consist of at least  
8 exons that can be assembled, through alternative splicing  
50 [30-32], into a number of variant mRNA molecules that have  
the potential to encode differing proteins, each having

mitogenic activity for the endothelial cell [33,34]. Both human and rodent cell lines and tissues have been characterized for the expression of these VEGF splice variants and the prominent forms found in adult tissues include transcripts that can encode for 121, 165 or 189 amino acid (AA) containing proteins (in humans) [35-38]. Other VEGF splice variants have been detected in much lower abundance, for example, a 145 AA- encoding transcript for VEGF has been found in human uterine and placental tissue [39-41] as well as a 206 AA -encoding transcript that was found in fetal liver and placenta [41,42]. Of this group of VEGF splice variants, all transcripts contain the first five VEGF exons as well as the last (eighth) exon but differ in the inclusion and/or arrangement of the sixth and seventh exon. Virtually identical VEGF splice variants have also been described in rodent tissues, however the variant rodent VEGF transcripts generally encode for a protein product containing one amino acid less than the human counterpart (see Figure 1) [28,43]. Using a RT-PCR screening method, we attempted to identify the VEGF mRNA splice variants that are expressed in rat and human penile tissues. Oligonucleotide primers designed to amplify cDNA from the first to the eighth exon of rat VEGF were used in a PCR amplification reaction of cDNA made from RNA extracted from rat lung or from rat penis. The RT-PCR amplification products were examined by electrophoresis on an agarose gel followed by ethidium bromide staining. As expected (Figure 2A), these primers amplified three distinct cDNA fragments of 564, 492 and 360 bp in size from the rat lung cDNA (corresponding to the expected 188, 164 and 120 rat VEGF AA-encoding isoforms) as well as a distinct cDNA fragment of 432 bp. All of these cDNA fragments were also amplified from the cDNA of rat penis. Although the RT-PCR screening method was not designed to be quantitative, there appeared to be a distinct difference in the abundance of these RT-PCR Products between rat lung and penis tissue. The most predominant of the VEGF cDNAs amplified from lung RNA encoded the 188 AA isoform of VEGF whereas the most predominant transcript amplified from penis RNA appeared to

5 be the one encoding the 164 AA isoform of VEGF (Figure 2A).  
Each of these cDNA fragments was individually cloned into  
10 plasmids so that they could be sequenced and confirmed as  
VEGF splice variants. The sequencing confirmed our  
5 identification of the 188, 164 and 120 AA forms as well as  
confirmed that the 432 bp amplification product was the VEGF.  
transcript variant encoding the 144 AA form of VEGF that was  
15 previously found only in uterine and placental tissues. More  
surprisingly in our survey of the cDNA clones resulting from  
20 RT-PCR amplification, we found one cDNA clone (330 bp)  
containing a novel splice variant of VEGF A that has never  
before been described (see Figure 1). This splice variant  
25 contained the entire first three exons of rat VEGF-A spliced  
to a partial exon 7 (now referred to as exon 7B) and was  
terminated by the entire exon 8. It is likely that the  
partial exon 7 included in this novel transcript (7B) was  
30 another of the many splice adoptions of the VEGF A transcript  
since a canonical splice donor sequence (CCGCAG/) [44] was  
present at the end of the region of exon 7A that was deleted  
from this particular splice variant. Although this splice  
variant must be present in much lower abundance than any of  
the better known forms, this novel VEGF A splice variant does  
have the potential to encode a 110 amino acids isoform of  
VEGF- A.

35 25  
Similar primer sets were utilized to amplify cDNA that was  
reverse transcribed from human penis RNA and from RNA  
40 extracted from a human prostate cancer cell line, LNCaP, that  
is known to express VEGF-A in abundance. Figure 2B shows the  
30 ethidium bromide stained agarose gel on which the  
amplification products from human penis cDNA, LNCaP cell cDNA  
or rat tissue (penis and lung) cDNA were electrophoresed.  
45 As can be seen from the results shown here, human penis (and  
human LNCaP cells) expresses the identical repertoire of VEGF  
35 splice variant isoforms that were found in the rat penis  
(including the 189, 165, 145 and 121 AA encoding isoforms).  
50 Moreover, these isoforms were present in similar abundance  
to the rat penis isoforms.

2. RNase Protection Assay to Confirm Relative Abundance  
of VEGF A Transcripts in Rat Penis

In order to confirm and better quantify that the predominant  
5 VEGF-A transcript splice variants expressed in rat penis  
differed significantly in abundance from the forms expressed  
in rat lung, we developed an RNase protection assay that  
would allow us to distinguish the relative abundance of the  
15 different rat VEGF-A splice variants in RNA samples.  
10 <sup>32</sup>P-radiolabeled probes for the 188 AA or the 164 AA splice  
variant of rat VEGF A cDNA were prepared by in vitro  
transcription of expression plasmids containing these  
respective cDNA inserts. The probes were individually  
20 hybridized to RNAs extracted from rat lung or rat penis and  
15 were then digested with a nuclease cocktail and  
electrophoresed on a polyacrylamide gel. The gel was exposed  
25 to film for autoradiography and the signal intensity of the  
protected fragments on this assay demonstrates the relative  
abundance of the corresponding transcript.

20 This two-probe assay was designed to demonstrate the presence  
of the VEGF isoforms through the detection of certain  
"diagnostic" fragments. For example, when using the larger  
transcript as a probe (the 188 splice isoform), the presence  
35 25 of a protected fragment at 564 bp would distinguish and  
confirm the presence of the 188 splice variant in the test  
mRNA specimen whereas the presence of a protected 150 bp  
fragment in the digest would distinguish the presence of the  
40 164 splice variant (see Diagram at lower part of Figure 3A).  
30 Likewise, when using the smaller transcript as a probe (164  
splice isoform), the presence of a protected fragment of 492  
bp would confirm the presence of the 164 splice variant in  
45 the test specimen (See Diagram at lower part of Figure 3B).

35 The results (Figures 3A and 3B) of this RNase protection  
assay showed that, in rat lung, the most abundant splice  
50 variants of VEGF-A mRNA are for the 188 and the 164 isoforms,  
confirming the earlier experiment involving RT-PCR



5 amplification of VEGF A isoforms (Figure 2A/2B) as well as  
other reports [39]. In rat penis mRNA, we did not observe  
significant protection of a 564 bp fragment nor the 414 bp  
10 fragment using the larger splice isoform probe, indicating  
5 a much lower abundance of the 188 splice variant mRNA in  
penis mRNA compared to lung as well as a low abundance of the  
144 splice variant in penis mRNA. With the smaller transcript  
as a probe, we were able to identify the presence of  
15 protected fragments at 492 bp and 342 bp, confirming the more  
10 abundant presence of the 164 and 120 isoform splice variants  
in penis mRNA. Again, this observation supports the RT-PCR  
experiments on rat penis in which we found that the 164 and  
20 120 splice isoforms appeared to be the most abundant VEGF  
splice variants present in rat penis mRNA (Figure 2A/2B).

15

3. Expression of VEGF Splice Variants 144/145 and 205/206  
25 in Adult Male Tissues

A standard RT-PCR technique was used to detect VEGF splice  
isoforms. Using an upstream primer starting in VEGF exon 1  
20 and a downstream primer from VEGF exon 8, RT-PCR was  
performed on RNAs extracted from mature rat lung and penis  
30 as well as from a human prostate cancer cell line LNCaP. When  
the RT-PCR reaction products were analyzed by agarose gel  
electrophoresis, 4 major bands were detected from each of the  
35 reactions (Figure 4). The size of 3 of these bands (at  
360/363, 492/495 and 564/567 basepairs (rat/human)) would  
correspond to the expected transcript sizes encoding the  
120/121, 164/165, and 188/189 AA isoforms of VEGF-A. However,  
40 an additional band at 432/435 bp, clearly visible in the  
30 reaction products from rat lung/penis and human penis/LNCaP  
cells, would more correspond with the expected size of the  
144/145 splice form of VEGF-A (Figure 4), previously only  
45 detected in placental and uterine tissues (sheep and humans)  
(41,42,39) and in cultured human endometrial carcinoma cells  
35 (39). The amplification products from these reactions were  
individually cloned into plasmid sequencing vectors and were  
sequenced. The sequences obtained confirmed our  
50 identification of the 120/121, 165/165, and 188/189 AA splice

5 isoforms as well as the presence of the supposedly more rare  
144/145 splice variant in the RNAa from these cells/tissues.

10 In the results of the previous RT-PCR reaction, we did not  
5 find the clear presence of a larger, 615 bp product, that  
would have resulted from the corresponding amplification of  
the VEGF-A splice isoform encoding a 205/206 AA peptide.  
15 However, the RT-PCR reaction was subsequently repeated using  
the same upstream primer (starting from exon 1) with a  
10 different downstream primer, (complimentary to the last five  
bases of exon 6A and continuing into the first 19 bases of  
exon 6B). The 6B exon of VEGF-A is found only in the VEGF  
20 205/206 splice isoform, therefore this second primerpair was  
designed to selectively amplify the other supposedly rare  
15 isoform, VEGF 205. The application of this second primer pair  
showed a band at 433 basepairs in the amplification products  
25 from RNAs extracted from rat lung and penis (Figure 5), a  
size that would be expected if the VEGF 205/206 splice  
isoform was present in the RNAs. The identity of this  
20 fragment was also confirmed, at least for the rat lung, by  
cloning and sequencing the 433 bp amplification product. This  
30 sequence showed complete homology to the rat VEGF-205 mRNA  
splice variant.

35 In conclusion, these results indicate that the rarer splice  
variants of VEGF-A (encoding the 144/145 and 205/206 AA  
forms) are probably more widely expressed in adult rat and  
human tissues than previously suspected. The PCR reaction  
40 conditions under which these rare splice variants of VEGF  
30 were detected were not so vigorous as to amplify such rare  
transcripts as those referred to as "basal" in nature.  
Although the transcript encoding the 144/145 splice variant  
was seemingly amplified less than the 120/121, 164/154, or  
45 188/189 variants, it was well within detection limits of  
35 simple DNA staining techniques. However, the apparently lower  
abundance expression of VEGF 144/145 and 205/206 in these  
tissues (when compared to the more predominant VEGF splice  
50 variants) probably explains the failure of other

investigators to identify their presence, especially in tissues that have been subject to repeated VEGF mRNA characterization, such as lung.

#### Experimental Discussion

Erectile function is dependent on the development of an appropriate penile vasculature and maintenance of an effective blood supply to the erectile tissues of the penis. The development and growth of a vascular system is referred to as angiogenesis and vasculogenesis. These processes are governed by several types of growth factors, including basic FGF (bFGF) and VEGF. Previously, we described the abundant presence of a heparin-binding growth factor in rat penis that had a functional activity that could be neutralized by antibodies to bFGF, suggesting that this substance was indeed bFGF [45]. Here we characterized the mRNA of rat and human penis to evaluate whether any of the many mRNA splice isoforms of VEGF are expressed in penile tissues and to determine which of the multiple splice isoforms might be the most abundantly expressed in the penis.

These results show that several different mRNA splice variants of VEGF-A mRNA are expressed in both rat and human penis and that there appears to be a distinct difference in the abundance of the different VEGF-A splice isoforms when compared to another rat tissue (rat lung) in which VEGF-A expression is known to be abundant. Whereas it has been confirmed that the rat lung expresses most abundantly an mRNA encoding the 188 splice variant, the rat penis, in contrast, expresses the 164 splice variant of VEGF-A mRNA at greatest abundance. Other VEGF splice variants, including the previously described 120 splice variant are also expressed at much lower levels by the lung and the penis. The ability to detect the presence of the 144 VEGF-A splice variant which was previously found only in placenta and some female reproductive tissues (uterus) was also surprising [39-42].

Moreover, the sequencing studies of a large number of VEGF cDNAs that were obtained following RT-PCR amplification of rat penis mRNA revealed the presence of a new splice variant of VEGF-A which has the more unusual characteristic of retaining the first 3 exons (instead of the first 5) as well as having an apparent splice within the 7<sup>th</sup> exon. This splice variant is likely to be present in extremely low abundance, as we never detected a significant 330 bp amplification product in our RT-PCR experiments, nor was the corresponding protected exon fragments in our RNase protection experiments ever found. While the possibility was considered that this unusual splice variant of VEGF might not be able to produce an angiogenic peptide, it is of interest that another rare splice variant of (mouse) VEGF mRNA has also been described, containing only the first three exons of VEGF. This splice variant (VEGF 115) has been shown to encode a peptide that is able to bind to VEGF receptor and activate mitogenesis of endothelial cells [46]. Therefore, the unusual VEGF splice variant (VEGF 110) observed in these studies, although seemingly rare and low in abundance, probably has the potential to produce a functional VEGF peptide.

The recent approval by the FDA of Sildenafil citrate as the first oral therapy for erectile dysfunction has become a landmark for the development of pharmacotherapy for erectile dysfunction. However, all current pharmacologic treatments of erectile dysfunction consist of "on-demand" medications that produce temporary erections. At this time there is no curative treatment for erectile dysfunction. The work in this project is based on our conceptualization of the induction of vasculogenesis in the erectile tissue as a potential cure for the reduction of vascular elements frequently encountered in vasculogenic erectile dysfunction. In this descriptive study, VEGF-A mRNA expression was surveyed in rodent and human penis. The present characterization of the various VEGF isoforms in the erectile tissues is motivated by our interest in defining the angiogenic growth factors that regulate

5 penile vasculogenesis and potentially exploiting these  
findings for therapeutic applications to treat human  
impotence. One could conceivably consider the therapeutic  
10 application of VEGF peptides to stimulate further penile  
5 vascular development as has been contemplated for other  
vascular insufficiency conditions [9,23]. Likewise, use of  
VEGF expression vectors provides a novel gene therapeutic  
15 approach for the curative treatment of erectile dysfunction,  
an approach that is being contemplated for other gene  
10 products involved in the response [47,48]. By identifying the  
predominant angiogenic peptides naturally expressed in the  
erectile tissues of the penis, this goal is one step closer.

15

References

1. Impotence. NIH consensus statement 1992; 10(4) :1-31.
2. Christ GJ. The penis as a vascular organ. Urol Clin North Amer 1995; 22(4) :727-745.
3. Karadeniz T, Topsakal M, Aydogmus A, Gulgun C, Aytekin Y, Basak D. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic impotence. Urol Int 1996; 57(1) :58-61.
4. Nehra A, Hall SJ, Basile G, Bertero EB, Moreland R, Toselli P, de las Morenas A, Goldstein I. Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 1995; 153(4) :1140-1146.
5. Aydos K, Baltaci S, Saglam M, Tanyolac A, Anafarta K, Beduk Y, Gogus O. Ultrastructural changes of corpora cavernosa in vascular erectile dysfunction. Int Urol Nephrol 1996; 28(3) :375-385.
6. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, Krane RJ, Udelson D, Saenz de Tejada I, Moreland RB. Mechanisms of venous leakage; a prospective clinicopathological correlation of corporeal function and structure. J Urol 1996; 156(4) :1320-1329.
7. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsburn M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-745.
8. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3(2) :158-164.
9. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M. Vascular endothelial growth factor administration in chronic

5 myocardial ischemia. Am J Physiol 1996; 270 (5/2) :H1791-1802.

10 10. Tsurumi Y, Murohara T, Krasinski K, Chen Witzendichler B, Kearney M, Couffinhal T, Isner JM. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nature Med 1997; 3(8):879-886.

15 11. De Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlation with proliferation and angiogenesis. J Pathol 1998; 184(1):53-57.

20 12. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol International 1995; 19(5):431-444.

25 13. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E, Varda-Bloom N, Nass D, Engelberg S, Eldar M, Belkin M, Savion N. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. JACC 1993; 7:2001-2006.

30 14. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998; 49(2):189-195.

35 15. Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, Thomas KA. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci 1990; 87:2628-2632.

40 16. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11:73-91.

45 17. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor

50

55

5 growth factor (-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57:963-969.

10 5 18. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114:521-532.

15 10 19. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, Ferris B, Sanborn T, Isom P, Isom OW, Crystal RG, Rosengart TK. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. 20 J Vasc Surg 1998; 27(4):699-709.

25 20. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, Symes JF, Ferrara N, Isner JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit of hind limb ischemia. Biochem & 30 Biophys Res Commun 1996; 227(2):628-635.

35 21. Mulhauser J, Merrill M, Pili R, Maeda H, Basic M, Bewig B, Passaniti A, Edwards N, Crystal R, Capogrossi M. VEGF 164 expressed by a replication-deficient recombinant adenovirus vector induces vasculogenesis in vivo. Circul Res 1995; 77:1077-1086.

40 22. Baffour R, Berman J, Garb J, Sang WR, Kaufmann J, Friedmann P. Enhanced vasculogenesis and growth of 30 collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16(2):181-191.

45 35 23. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes J, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor, augments revascularization in a rabbit ischemic hind 50



limb model. J Clin Invest 1994; 93(2):662-670.

24. Isner JM, Walsh K, Symes JF, Brogi E, Jurayi D. Arterial gene therapy for therapeutic vasculogenesis in patients with peripheral artery disease. Circulation 1995; 91:2687-2692.

25. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchardt M, Devris G, Cao YC, Olsson C, Shabsigh R. Apoptosis in the rat penis after penile denervation. J Urol 1997; 158:626-630.

26. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162(1):156-159.

27. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, Kozlowski JM, Lee C. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995; 55(11):2431-2437.

28. Basic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 1990; 12:11-15.

29. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB. Localization of the human vascular endothelial factor gene, VEGF, at chromosome 6p12. Hum Genet 1996; 97:794-797.

30. Holliday R, Murray V. Specificity in splicing. Bioessays 1994; 16(10):771-774.

31. Smith CWJ, Patton JG, Nadal-Ginard B. Alternative splicing in the control of gene expression. Annu Rev Genet 1989; 23:527-577

32. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family:

5 identification of a fourth molecular species and  
characterization of alternative splicing of RNA. Mol Endo  
1991; 5(12):1806-1814.

10 5 33.Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual  
regulation of vascular endothelial growth  
factor-bioavailability by genetic and proteolytic mechanisms.  
J Biol Chem 1992; 267(36):26031-26037.

15 10 34.Neufeld G, Cohen T, Gitay-Goren H, Poltorak Z, Tessler S,  
Sharon R, Gengrinovitch S, Levi BZ. Similarities and  
differences between the vascular endothelial growth factor  
20 (VEGF) splice variants. Cancer & Metast Rev 1996; 15:153-158.

15 35.Bekmann RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena  
A, Clark WC, Robertson JT, Ali IU, Oldfield EH. Expression  
25 of the vascular permeability factor/vascular endothelial  
growth factor gene in central nervous system neoplasma. J  
20 Clin Invest 1993; 91:153-159.

30 36.Wizigmann-Voos S, Breier G, Rissau W, Plate KH.  
Up-Regulation of vascular endothelial growth factor and it's  
receptors in von Hippel-Lindau Disease-associated and  
25 sporadic hemangioblastomas. Cancer Res 1995; 55:1358-1364.

37.Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS,  
Smith SK. Localization and quantification of vascular  
endothelial growth factor messenger ribonucleic acid in human  
40 myometrium and leiomyomata. J Clin Endo & Metabol 1995;  
30 80(6):1853-1858.

45 38.Cullunan-Bove A, Koos RD. Vascular endothelial growth  
factor/vascular permeability factor expression in the rat  
35 uterus: rapid stimulation by estrogen correlates with  
estrogen-induced increases in uterine capillary permeability  
and growth. Endocrinol 1993; 132(2):829-837.

50

55

5 39. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch  
D, Schofield JP, Fountain SA, Boocock CA, Smith SK.  
Identification and localization of alternately spliced mRNAs  
10 for vascular endothelial growth factor in human uterus and  
5 estrogen regulation in endometrial carcinoma cell lines. Biol  
Reprod 1993; 48(5):1120-1128.

15 40. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G,  
Vlodavsky I, Keshet E, Neufeld G. VEGF 145, a secreted  
10 vascular endothelial growth factor isoform that binds to  
extracellular matrix. J Biol Chem 1996; 272(11):7151-7158.

20 41. Cheung CY, Singh M, Ebaugh MJ, Brace RA. Vascular  
endothelial growth factor gene expression in ovine placenta  
15 and fetal membranes. Am J Obstet Gynecol 1995;  
173(3/1):753-759.

25 42. Anthony FW, Wheeler T, Elcock CL, Pickett M, Thomas EJ.  
Short report: Identification of a specific pattern of  
20 vascular endothelial growth factor mRNA expression in human  
placenta and cultured placental fibroblasts. Placenta 1994;  
30 15(5):557-561.

35 43. Redmer DA, Dai Y, Li J, Charnock-Jones DS, Smith SK,  
25 Reynolds LP, Moor RM. Characterization and expression of  
vascular endothelial growth factor (VEGF) in the ovine corpus  
luteum. J Reprod & Fertil 1996; 108:157-165.

40 44. Mount SM. A catalogue of splice junction sequences.  
Nucleic Acids Research 1982; 10(2):459-472.

45 45. Te AE, Santarosa RP, Koo HP, Buttyan R, Greene L, Kaplan  
SA, Olsson CA, Shabsigh R. Neurotrophic factors in the rat  
35 penis. J Urol 1994; 152:2167-2172.

50 46. Sugihara T, Wadhwa R, Kaul SC, Mitsui Y. A novel  
alternatively spliced form of murine vascular endothelial

5 growth factor, VEGF 115. J Biol Chem 1998; 273(5):3033-3038.

10 47. Garban H, Marquez D, Magee T, Moody J, Rajavashisth T,  
Rodriguez JA, Hung A, Vernet D, Rajfer J, Gonzalez-Cadavid  
5 NF. Cloning of rat and human inducible penile nitric oxide  
synthase. Application for gene therapy of erectile  
dysfunction. Biol Reprod 1997; 56(4):954-963.

15 48. Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman  
A, Geliebter J. Intracorporal injection of hSlo cDNA in rats  
produces physiologically relevant alterations in penile  
20 function. Am J Physiol 1998; 275(2PT1):H600-H608.

15 49. Olofsson, B., et al. Proc. Natl. Acad. Sci. USA 1996; 93,  
2576-2581.

25 50. Joukov, V., et al. EMBO J. 1996; 15(7), 1751.

20 51. Terman, B.I., Dougher-Vermazen, M. Cancer Metastasis Rev.  
1996; 15(2), 159-163.

30 52. Neufeld, G., et al. Prog. Growth Factor Res. 1994; 5(1),  
89-97.

25 53. Thomas, K.A., J. Biol. Chem. 1996; 271(2), 603-606.

35 54. Tischer, E., et al. J. Biol. Chem. 1991; 266(18), 11947-  
11954.

40 30

45

50

55

## Claims

5

10

15

20

25

30

35

40

45

50

55

5

## What is claimed:

10

5

1. A method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

15

10

2. A method of treating erectile dysfunction in a subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction.

20

15

3. A method of increasing or maintaining the density of vascular structures in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis.

25

20

4. The method of claim 1, 2 or 3, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.

30

25

5. The method of claim 1, 2 or 3, wherein the vascular endothelial growth factor is administered intravenously, topically, transdermally, orally or by injection.

35

30

6. The method of claim 1, 2 or 3, wherein the vascular endothelial growth factor is injected into the penis.

40

35

7. The method of claim 1, 2 or 3, wherein the vascular endothelial growth factor is injected into corpora cavernosa tissue.

45

40

8. The method of claim 1, 2 or 3, wherein the vascular endothelial growth factor is injected into corpus spongiosum tissue.

50

55

5

10

15

20

25

30

35

40

45

50


55

9. A method of increasing or maintaining the blood supply in the penis of a subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis.
10. The method of claim 8, wherein the nucleic acid comprises a vector.
11. A method of increasing or maintaining the blood supply in the genital area of a female subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's genital area.

1/7

## FIGURE 1


## VEGF-A TRANSCRIPT SPLICE VARIANTS






2/7

FIGURE 2A




3/7

FIGURE 2B



4/7

FIGURE 3A




SUBSTITUTE SHEET (RULE 26)

5/7

FIGURE 3B


Probe VEGF 164



SUBSTITUTE SHEET (RULE 26)


6/7

FIGURE 4



7/7

FIGURE 5



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/01535

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 38/00, 38/24, 38/27  
US CL :514/12; 530/399

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12; 530/399

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

caplus, uspatfull  
vegf, vascular endothelial growth factors, erection, impotence, erectile dysfunction

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	WO 99/56785 A2 (UNIVERSITY OF PITTSBURGH) 11 November 1999 (11-11-99), see entire document.	1-11
A,P	WO 99/60630 A1 (GLAXO GROUP LIMITED) 25 November 1999 (25-11-99), see entire document.	1-11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*B\* earlier document published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

## \*\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

## \*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

## \*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

## \*A\*

document member of the same patent family

Date of the actual completion of the international search

24 APRIL 2000

Date of mailing of the international search report

16 MAY 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:  
*Cynthia Lawrence Fox*  
Cybille D-Muirheid

Telephone No. (703) 308-0196

You looked for the following: (Columbia)<APPLICANT> AND (Shabsigh)<INVENTOR>  
3 matching documents were found.

To see further result lists select a number from the JumpBar above.

Click on any of the Patent Numbers below to see the details of the patent

Basket	Patent	Title
<input type="checkbox"/>	<b>Number</b>	
<input type="checkbox"/>	<a href="#">EP1150698</a>	USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE TREATMENT OF ERECTILE DYSFUNCTION
<input type="checkbox"/>	<a href="#">AU2623700</a>	Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
<input type="checkbox"/>	<a href="#">WO0043029</a>	USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE TREATMENT OF ERECTILE DYSFUNCTION

To refine your search, click on the icon in the menu bar  
Data supplied from the [esp@cenet](#) database - I2